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Abstract
Background: Osteoclast-like giant cells (OLGCs) are a rare histologic finding within a tumor of the breast. Although
there has been discussion as to the pathogenesis and prognosis related to this finding, our understanding of its
significance remains inconclusive. Clear cells are another unique histologic finding in breast tumors and are typically
associated with tumors arising in other organs such as renal cell carcinoma.
Case presentation: This is a case report of a 64-year-old female who presented with one tumor identified as
invasive ductal carcinoma with a combination of OLGCs and clear cell features.
Conclusions: To our knowledge, this combination of findings has not been previously described in the literature
and therefore represents another morphologic manifestation of breast carcinoma. As patients are diagnosed earlier
and live longer, a growing number of these rare variants may be recognized and provide opportunities to further
our understanding of the associated molecular pathways which could contribute to the possibility of therapeutic
intervention.
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Background
Breast cancer is the most commonly diagnosed noncuta-
neous cancer and the second leading cause of cancer
death among women worldwide [1]. In the USA, the inci-
dence of breast cancer in women increased from 105.1
per 100,000 in 1975 to 129.6 per 100,000 in 2012 [2, 3].
Simultaneously, the mortality has decreased by 30 % since
the 1990s resulting in a prevalence of over 3.1 million di-
agnosed breast cancer cases in the USA as of 2014 [1, 4].
Breast cancer progression is a complex and multifaceted
subject. Prognosis is based on a combination of factors
including lymph node status, tumor size, and histology, as
well as expression of hormone and growth receptors
[5–7]. Histologic reports and proteomic analysis have de-
termined that most breast malignancies arise from epithe-
lial tissue and that ductal and lobular carcinomas make up
75 and 15 % of invasive cancers, respectively [2, 8, 9]. Sev-
eral rarer subtypes including mucinous, clear cell, OLGCs,
and pleomorphic carcinomas account for the remaining
10 % of all cases and continue to be relatively unexplored
due to few reported cases and a lack of large statistically
significant studies [10]. As the prevalence of breast cancer
increases, there should be a simultaneous escalation in the
number of these historically rare variants and the need to
classify them appropriately as molecular pathways of vary-
ing cancers may have important implications on prognosis
and treatment.
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Introduction to osteoclast-like giant cells
OLGCs are large multinucleated cells that resemble the
morphology and function of histiocytic osteoclasts found
in bone [11]. They have typically been associated with
several cancers including gallbladder, liver, and thyroid
[12–14]. Agnatis first reported OLGCs as a component
of a primary breast malignancy in 1979 [15]. They are
found in only 0.5–1.2 % of all primary breast carcinomas
and to date approximately 200 cases of OLGCs associ-
ated with breast malignancy have been reported [16, 17].
OLGCs have been detected mostly in association with
invasive metaplastic carcinoma but may be seen with
other histologic variants including lobular, tubular, mu-
cinous, and papillary patterns [10, 16].
Introduction to clear cells
Clear cells are recognized by histologic findings that re-
sult from the removal of cytoplasmic inclusions during
tissue processing. Various cellular components may re-
sult in a clear appearance and histochemical staining can
be used to determine the contents of the cell, although
it is not routinely performed. Some common contents
include lipid, mucin, or glycogen [18, 19]. Clear cells are
traditionally found in carcinomas of the kidney, ovary, va-
gina, cervix, endometrium, and salivary glands [20–22].
Rarely, clear cells have also been identified in several types
of breast carcinomas including ductal, lobular, adenocar-
cinoma, squamous cell carcinomas, and metastases from
other organs [23, 24]. Hull first described the presence of
glycogen-rich clear cells as a separate histologic category
of invasive ductal carcinoma of the breast in 1981 [18].
Fewer than 150 cases have been reported in the literature
as of 2014 [25].
This is a case report of a patient who presents with a
previously undescribed combination of these two unique
histologic categories of invasive ductal carcinoma. We
also provide a review of the literature on these rare char-
acteristics of breast carcinoma that have been previously
reported in separate studies.
Case presentation
A 64-year-old Caucasian female with no personal or fam-
ily history of breast or ovarian cancer presented for rou-
tine screening mammography. Imaging showed an
irregular 4-cm mass in the upper outer quadrant of the
right breast containing several pleomorphic calcifications
(Fig. 1). This lesion was assigned a Breast Imaging Report-
ing and Data System (BIRADS) score of 4, representing a
suspicious abnormality where biopsy is recommended
[26]. Ultrasound (US) identified a mass with angular mar-
gins, calcifications, and hypervascularity suspicious for in-
vasive ductal carcinoma (Fig. 2). The lesion was sampled
using vacuum-assisted US-guided biopsy with a 14-gauge
needle, and the biopsy was placed in 10 % neutral buffered
formalin and forwarded to pathology for processing.
Grossly, the biopsy consisted of four red yellow cylin-
drical fibrofatty soft tissue cores ranging from 1.5 to
1.7 cm in length. Hematoxylin and eosin (H&E) sections
were microscopically examined and demonstrated inva-
sive nests of cuboidal cells with ample amphiphilic cyto-
plasm. In addition, large multinucleated cells with pink
cytoplasm, intracellular granular inclusions, and in-
creased nuclear to cytoplasmic ratio were identified.
Small polygonal cells with centrally located nuclei and
clear cytoplasm were noted as well as areas of central
necrosis and associated calcifications (Figs. 3 and 4).
Immunohistochemical staining demonstrated tumor
cells to be positive GATA3 (Fig. 5a), confirming the lesion
to be ductal cell in origin. In addition, mammaglobin was
focally positive (Fig. 5b) indicating the tumor to be breast
tissue and not a metastasis from another site. Smooth
Fig. 1 Initial MLO view mammography demonstrating an irregularly
bordered mass (left, arrow). Magnified view of the right breast
showing several pleomorphic microcalcifications (right, arrow)
contained within the mass
Fig. 2 Ultrasound image of right breast mass where several small
calcifications can be seen (arrow), representing an uncommon
sonographic finding
Zagelbaum et al. World Journal of Surgical Oncology  (2016) 14:227 Page 2 of 6
muscle myosin heavy chain was negative, verifying the
tumor architecture to be abnormal and invasive (Fig. 5c).
These overall findings were consistent with invasive ductal
carcinoma with OLGCs and clear cell features. This diag-
nosis was corroborated by an outside, fellowship-trained
breast pathologist. Further immunohistochemical staining
found the sample to be positive for estrogen and proges-
terone receptors and negative for Human Epidermal
Growth Factor Receptor 2 (HER2).
Discussion and review of the literature
Osteoclast-like giant cells
OLGCs in association with breast tumors are believed to
represent a fusion of several cells of monocyte lineage
located in the stroma. The significance of this finding is
inconclusive. The 5-year survival rate is about 70 % ver-
sus an average overall survival rate of 72 % for similarly
staged breast carcinomas [3, 10]. In six cases of invasive
carcinomas with OLGCs, Holland did not find an excep-
tionally different clinical course when compared to typ-
ical invasive carcinomas [27]. Agnantis described eight
patients with similar results in terms of prognosis and
outcome [15]. Other investigations have shown that the
average size of an OLGC-containing breast carcinoma is
3 cm and that over one third of patients have axillary
metastasis [27]. Cai reviewed 42 cases of OLGC in
breast carcinoma and found a majority had a relation-
ship to marked angiogenesis and that this finding por-
tended a poorer prognosis [27, 28].
Much debate and speculation has gone into the origin
of OLGCs and their relationship to breast cancer [15, 29].
Markopoulos hypothesized that chemotactic agents pro-
duced by the tumor may recruit histiocytes to the region,
resulting in this unique histological subtype of breast car-
cinoma [30]. Interestingly, one study found that OLGCs
isolated from an invasive breast cancer were able to digest
bone directly in vitro. These were the first cells observed
to resorb bone that were not directly harvested from osse-
ous tissue. Unlike osteoclasts, which require the presence
of osteoblasts to be stimulated, these OLGCs were directly
activated by the presence of parathyroid hormone.
Additionally, the cells were not inhibited by calcitonin,
demonstrating another key distinction between OLGCs
and osteoclasts [11]. These differences provide important
clues into the origin of these OLGCs, and more research
may be warranted to clarify the significance of these cells.
Fig. 3 H&E stain demonstrating invasive ductal carcinoma. a Both OLGCs (white arrows) and clear cells (black arrows) are present throughout the
tumor. b Large focus of OLGCs. c Predominant clear cell features
Fig. 4 H&E stain demonstrating central necrosis and
associated calcifications
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Breast carcinoma with clear cell features
Clear cells are a rare histologic finding in a primary
breast cancer and can be seen in several tumor types.
Variants reported within primary breast tumors include
glycogen-rich clear cell carcinoma (GRCCC), signet-ring,
lipid-filled, and secretory carcinomas. Of these, GRCCC is
the most common clear cell variant in breast cancer [30].
The current diagnostic criterion for a GRCCC is debat-
able. One early study defined GRCCC tumors as contain-
ing greater than 50 % clear cells [31]. However, the World
Health Organization (WHO) definition is a tumor in
which greater than 90 % of the neoplastic cells contain
clear cytoplasm filled with glycogen [10], reflecting the
variability of cell composition seen in breast tumors.
There is conflicting evidence regarding the survival
rate of patients diagnosed with GRCCC. Some research
suggests a poor prognosis. One case series found that
five of its six cases had axillary lymph node involvement
at the time of diagnosis and that all five of these patients
succumbed to the disease within 7 years [31]. By com-
parison, the overall 5-year survival rate of all types of
breast cancer was 89.4 % between 2005 and 2011 [32].
WHO identifies GRCCC to have a more aggressive course
with axillary involvement than other ductal carcinoma vari-
ants. However, they acknowledge that prevalence is not yet
sufficient to establish large multimodal studies on these re-
lationships [10]. In contrast, Hayes matched GRCCC to
other types of invasive breast carcinoma by tumor stage
and grade and demonstrated no difference in outcomes
[33]. Overall, the consensus is that there have not been
enough reported cases to draw significant conclusions on
GRCCC’s effect on patient outcomes warranting further in-
vestigation on the subject.
The research in the clinical progression of GRCCC is
also conflicted. A few case studies suggest low rates of
recurrence following tumor excision. Hull presents a
case where a patient had no axillary lymph node in-
volved which contained any evidence of neoplasm after
mastectomy [18]. Sorensen and Paulsen describe a pa-
tient without recurrence or metastasis after a follow-up
period of 6 months [34]. Shirley outlines a case where
no evidence of metastatic disease was found after
18 months of follow-up [35]. However, Kuroda identifies
a propensity for GRCCC to metastasize in a study that
aggregated over 700 cases of breast carcinoma in which
20 cases were GRCCC. In these cases, tumor size was an
average of 2.6 cm and 35 % of patients had positive
lymph nodes in the axillary region [36].
Other clear cell variants tend to have a more insidious
progression. Signet-ring cell carcinoma of the breast
contains primarily mucinous inclusions and has a 5-year
survival rate of 45–60 % [37]. Lipid-rich carcinoma of
the breast also has an aggressive course and poor prog-
nosis, with a 33 % 5-year survival rate [38]. Secretory cell
carcinoma of the breast has axillary lymph node metas-
tasis in 15–30 % of all cases [19]. Overall, studies have
indicated an incomplete understanding of the pathogen-
esis and prognosis associated with clear cell features in
invasive ductal carcinoma of the breast.
Additional case reports imply that underreporting as
well as misdiagnosis may be prevalent. Ovanez suggests
clear cell carcinoma may mimic the appearance of
Fig. 5 a Stain demonstrating positive for GATA3. b Focally positive mammaglobin stain, confirming the tumor to be breast in origin. c Stain for
smooth muscle myosin heavy chain only present in arteriole walls, demonstrating neovascular changes in tumor
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pseudo-lactating changes in a premenopausal female or
reflect benign changes of the breast at any age [25].
Markopoulos reported a case of a woman whose mammo-
gram revealed a 3.5-cm lobular mass which was originally
misdiagnosed to be a fibroadenoma but was finally diag-
nosed as a clear cell carcinoma 4 years later [30]. Aboum-
rad identified an example where clear cells may be
confused with lipid-filled macrophages in fat necrosis of
the breast [39]. Metastatic clear cell carcinomas originat-
ing in other origins such as the kidney can also mimic
clear cell features found in breast carcinoma [23].
Conclusions
In summary, this paper outlines our current understand-
ing of two rare variants of breast carcinoma and pro-
vides a case study involving a unique histologic finding
that has not been previously reported. The significance
of cytology in the clinical progression of rare tumors of
the breast is incompletely understood. The literature to
date suggests that certain cell types of breast cancer may
correlate with a poorer prognosis. As patients are diag-
nosed earlier and live longer, a growing number of these
rare variants may be recognized and provide opportun-
ities to further our understanding of the associated
molecular pathways which could contribute to the possi-
bility of therapeutic intervention. We believe it is im-
portant for health practitioners to be aware of these rare
tumors as they may impact the development of optimal
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